ZA986890B - Method and compositions for treating late phase allergic reactions and inflammatory diseases - Google Patents

Method and compositions for treating late phase allergic reactions and inflammatory diseases

Info

Publication number
ZA986890B
ZA986890B ZA986890A ZA986890A ZA986890B ZA 986890 B ZA986890 B ZA 986890B ZA 986890 A ZA986890 A ZA 986890A ZA 986890 A ZA986890 A ZA 986890A ZA 986890 B ZA986890 B ZA 986890B
Authority
ZA
South Africa
Prior art keywords
compositions
inflammatory diseases
allergic reactions
late phase
phase allergic
Prior art date
Application number
ZA986890A
Other languages
English (en)
Inventor
Tahir Ahmed
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of ZA986890B publication Critical patent/ZA986890B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ZA986890A 1997-08-04 1998-07-31 Method and compositions for treating late phase allergic reactions and inflammatory diseases ZA986890B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/904,565 US5980865A (en) 1995-08-18 1997-08-04 Method for treating late phase allergic reactions and inflammatory diseases

Publications (1)

Publication Number Publication Date
ZA986890B true ZA986890B (en) 1999-01-28

Family

ID=25419368

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA986890A ZA986890B (en) 1997-08-04 1998-07-31 Method and compositions for treating late phase allergic reactions and inflammatory diseases

Country Status (26)

Country Link
US (2) US5980865A (no)
EP (1) EP1003479B1 (no)
JP (1) JP2001511439A (no)
KR (1) KR100551773B1 (no)
CN (1) CN1092049C (no)
AR (1) AR005221A1 (no)
AT (1) ATE323500T1 (no)
AU (1) AU8684698A (no)
BR (1) BR9811823A (no)
CA (1) CA2298445C (no)
DE (1) DE69834256T2 (no)
DK (1) DK1003479T3 (no)
ES (1) ES2260843T3 (no)
HK (1) HK1030370A1 (no)
HU (1) HUP0003013A3 (no)
IL (1) IL134230A0 (no)
NO (1) NO20000558L (no)
NZ (1) NZ502498A (no)
PL (1) PL191796B1 (no)
PT (1) PT1003479E (no)
RU (1) RU2209624C2 (no)
SK (1) SK1172000A3 (no)
TW (1) TW585771B (no)
UA (1) UA75022C2 (no)
WO (1) WO1999006025A1 (no)
ZA (1) ZA986890B (no)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220909A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US6689748B1 (en) * 1998-04-08 2004-02-10 Theoharis C. Theoharides Method of treating mast cell activation-induced diseases with a proteoglycan
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
GB9917092D0 (en) 1999-07-22 1999-09-22 Ml Lab Plc Treatment of angiogenesis-dependent conditions
US20040230559A1 (en) * 1999-08-09 2004-11-18 Mark Newman Information processing device and information processing method
US20040224922A1 (en) * 1999-08-26 2004-11-11 Malcolm King Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
SE0001631D0 (sv) * 2000-05-04 2000-05-04 Sahltech Ab New use
EP1292314A2 (en) * 2000-05-23 2003-03-19 The Trustees of Columbia University in the City of New York Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans
DE60323973D1 (de) 2002-02-18 2008-11-20 Univ Southampton Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
EP1539192A1 (en) * 2002-04-24 2005-06-15 Medicarb AB Composition and kit for the treatment of inflammatory bowel diseases
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
EP1607095A1 (en) * 2003-03-25 2005-12-21 Sekisui Chemical Co., Ltd. Antipruritic composition for external use on skin
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US7923043B2 (en) * 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
JP2008512403A (ja) * 2004-09-10 2008-04-24 ファルマオリジン・アンパルトセルスカブ 局所的な気管、気管支、または肺胞の出血または喀血の治療方法
TW200621794A (en) * 2004-10-06 2006-07-01 Akzo Nobel Nv Pulmonary administration of an antithrombotic compound
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
HUE028691T2 (en) 2005-09-14 2016-12-28 Mannkind Corp A method for formulating a drug based on increasing the affinity of crystalline microparticle surfaces towards active ingredients
US8057840B2 (en) * 2006-01-25 2011-11-15 Tate & Lyle Ingredients Americas Llc Food products comprising a slowly digestible or digestion resistant carbohydrate composition
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
CN101095693B (zh) * 2006-06-29 2010-10-13 重庆华邦制药股份有限公司 治疗皮炎的复方药物
AU2008255565B2 (en) * 2007-05-31 2013-10-24 Paradigm Biopharmaceuticals Ltd Sulphated xylans for treatment or prophylaxis of respiratory diseases
AR072114A1 (es) 2008-06-13 2010-08-04 Mannkind Corp Un inhalador de polvo seco y sistema para suministro de farmacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
BRPI0914308B8 (pt) 2008-06-20 2021-06-22 Mannkind Corp sistema de inalação
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
US9176146B2 (en) * 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
MX2012006265A (es) * 2009-12-03 2012-07-25 Opko Health Inc Formulaciones disacaridas hipersulfatadas.
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
US20130203695A1 (en) * 2010-10-29 2013-08-08 Opko Health, Inc. Hypersulfated disaccharides to treat elastase related disorders
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
UY34069A (es) * 2011-05-12 2013-01-03 Aventis Pharma Sa Semuloparina para la prevención de tromboembolismo venoso en pacientes con cáncer que están recibiendo quimioterapia
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
JP6018640B2 (ja) 2011-10-24 2016-11-02 マンカインド コーポレイション 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
EP3981387A1 (en) 2011-12-07 2022-04-13 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2016040570A2 (en) 2014-09-12 2016-03-17 Children's Medical Center Corporation Dietary emulsion formulations and methods for using the same
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
RU2697844C9 (ru) 2014-11-25 2019-10-01 Аллерган, Инк. Стабилизированные композиции для офтальмологического применения, содержащие омега-3-кислоты
WO2018035050A1 (en) 2016-08-16 2018-02-22 Opko Pharmaceuticals, Llc Pure heptasulfated disaccharides having improved oral bioavailability
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
US11718609B2 (en) 2016-12-13 2023-08-08 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN114053251A (zh) * 2020-07-29 2022-02-18 苏州融析生物科技有限公司 硫酸化多糖吸入制剂及其在防治新冠病毒相关疾病中的应用
US20220211746A1 (en) * 2021-01-07 2022-07-07 Bionovax Corp. Special heparinoid composition, with repair, prophylactic and anti-inflammatory effects, applied to the lungs

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3405120A (en) * 1966-01-27 1968-10-08 Green Cross Corp Low molecular chondroitin sulfate and method for manufacturing the same
IT1195497B (it) 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
FR2584606A1 (fr) * 1985-07-12 1987-01-16 Dropic Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif
IT1230582B (it) * 1988-10-21 1991-10-28 Opocrin S P A Lab Farmabiologi Oliogosaccaridi di dermatan solfato ed eparina aventi attivita' antiaterosclerotica
US5032679A (en) 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
CZ232593A3 (en) * 1991-05-02 1994-07-13 Yeda Res & Dev Pharmaceutical preparation for preventing and/or therapy of pathological states
AU6204594A (en) * 1993-02-22 1994-09-14 Ulrich-Christoph Von Arnim Use of heparins for the treatment of inflammatory or immunological diseases
FR2704861B1 (fr) * 1993-05-07 1995-07-28 Sanofi Elf Fractions d'héparine purifiées, procédé d'obtention et compositions pharmaceutiques les contenant.
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
SE9303612D0 (sv) * 1993-11-02 1993-11-02 Kabi Pharmacia Ab New use
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma

Also Published As

Publication number Publication date
ES2260843T3 (es) 2006-11-01
JP2001511439A (ja) 2001-08-14
AU8684698A (en) 1999-02-22
NZ502498A (en) 2002-05-31
KR100551773B1 (ko) 2006-02-13
NO20000558L (no) 2000-03-14
CN1092049C (zh) 2002-10-09
PL191796B1 (pl) 2006-07-31
RU2209624C2 (ru) 2003-08-10
HUP0003013A3 (en) 2001-11-28
DE69834256D1 (de) 2006-05-24
AR005221A1 (es) 1999-04-28
US5980865A (en) 1999-11-09
BR9811823A (pt) 2000-08-15
PT1003479E (pt) 2006-08-31
EP1003479A4 (en) 2001-01-17
ATE323500T1 (de) 2006-05-15
PL338551A1 (en) 2000-11-06
CA2298445C (en) 2007-07-17
UA75022C2 (en) 2006-03-15
DK1003479T3 (da) 2006-07-31
EP1003479A1 (en) 2000-05-31
WO1999006025A1 (en) 1999-02-11
CN1269715A (zh) 2000-10-11
HK1030370A1 (en) 2001-05-04
IL134230A0 (en) 2001-04-30
CA2298445A1 (en) 1999-02-11
EP1003479B1 (en) 2006-04-19
DE69834256T2 (de) 2007-02-01
US6193957B1 (en) 2001-02-27
TW585771B (en) 2004-05-01
NO20000558D0 (no) 2000-02-03
KR20010022533A (ko) 2001-03-15
SK1172000A3 (en) 2001-03-12
HUP0003013A2 (hu) 2001-01-29

Similar Documents

Publication Publication Date Title
ZA986890B (en) Method and compositions for treating late phase allergic reactions and inflammatory diseases
AU1296099A (en) Methods and compositions for treating dermatoses
IL132145A0 (en) Methods and compositions for treating inflammatory bowel disease
GR3036364T3 (en) Compositions and methods for treating or preventing inflammatory diseases
BR9602695A (pt) Composto método e composição para tratamento de distúrbios hiperproliferativos
IL132758A0 (en) Methods for treating inflammation and inflammatory diseases using padprt
EP0960019A4 (en) METHOD FOR PRODUCING REPLICAS AND COMPOSITIONS USED THEREFOR
HK1031174A1 (en) Compositions and methods for treating diabetes
AU7582398A (en) Composition for treating skin conditions
AU2327599A (en) Compositions and methods for treating autoimmune diseases
AU3111700A (en) Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
AU9016898A (en) Methods and compositions for treatment of restenosis
EP0975654A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTIONS
AU6386499A (en) Method and composition for treatment of inflammatory bowel disease
AU3768795A (en) Method and compositions for hair treatment
AU4515001A (en) Compositions and methods for locally treating inflammatory diseases
AU6252699A (en) Composition and method for treating allergic diseases
EP0835092A4 (en) COMPOSITION AND TREATMENT FOR THE CONTROL OF Baldness
GB9710628D0 (en) Method for topical treatment of androgenic alopecia
SG65766A1 (en) Composition for preventing and treating gingival diseases
EP1124555A4 (en) METHOD FOR TREATING NEURODEGENERATIVE DISEASES
AU6391199A (en) Composition and method for treating allergic diseases
AU8049098A (en) Composition and methods for the treatment of inflammatory diseases
IL138654A0 (en) Methods and materials for treating inflammatory diseases